Literature DB >> 33007508

Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.

Samarth Patel1, Mohammad Bilal Siddiqui2, Jose Hernandez Roman3, Emily Zhang4, Emily Lee4, Steve Shen4, Masoud Faridnia3, Robert J Mintini5, Sherry Boyett5, Michael O Idowu6, Arun J Sanyal1, Velimir A Luketic1, Mohammad Shadab Siddiqui1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease,1 is independently associated with increased risk of cardiovascular disease (CVD), which is the leading cause of mortality in patients with NAFLD.2 This is likely caused by the centrality of the liver in lipid homeostasis. Prior cross-sectional studies have shown that NAFLD is associated with perturbations in lipid profile and atherogenic lipoprotein subparticles.3 Although statins improve lipid profile and CVD-associated mortality, residual CVD risk has been demonstrated in major statin trials.4,5 A key contributor to this residual risk is the limited ability of the standard lipid profile to precisely quantify atherogenic lipoprotein subparticles, such as small dense low-density lipoprotein (sdLDL), which might confer higher atherogenic risk. There are currently no studies evaluating the longitudinal impact of sdLDL on atherosclerotic events in NAFLD. Thus, we conducted a prospective study in patients with histologically confirmed NAFLD to better define the relationship among NAFLD, residual CVD risk, and sdLDL.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33007508      PMCID: PMC8822885          DOI: 10.1016/j.cgh.2020.09.039

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  6 in total

1.  Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.

Authors:  Mohammad Bilal Siddiqui; Tamoore Arshad; Samarth Patel; Emily Lee; Somaya Albhaisi; Arun J Sanyal; R Todd Stravitz; Carolyn Driscoll; Richard K Sterling; Trevor Reichman; Chandra Bhati; Mohammad Shadab Siddiqui
Journal:  Hepatology       Date:  2019-03-29       Impact factor: 17.425

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

3.  Statins do not decrease small, dense low-density lipoprotein.

Authors:  Cheol Ung Choi; Hong Seog Seo; Eun Mi Lee; Seung Yong Shin; Un-Jung Choi; Jin Oh Na; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Seung-Woon Rha; Chang Gyu Park; Dong Joo Oh
Journal:  Tex Heart Inst J       Date:  2010

4.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.

Authors:  Mohammad S Siddiqui; Michael Fuchs; Michael O Idowu; Velimir A Luketic; Sherry Boyett; Carol Sargeant; Richard T Stravitz; Puneet Puri; Scott Matherly; Richard K Sterling; Melissa Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-13       Impact factor: 11.382

Review 5.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

6.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  6 in total
  1 in total

1.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.

Authors:  Ansel Shao Pin Tang; Kai En Chan; Jingxuan Quek; Jieling Xiao; Phoebe Tay; Margaret Teng; Keng Siang Lee; Snow Yunni Lin; May Zin Myint; Benjamin Tan; Vijay K Sharma; Darren Jun Hao Tan; Wen Hui Lim; Apichat Kaewdech; Daniel Huang; Nicholas Ws Chew; Mohammad Shadab Siddiqui; Arun J Sanyal; Mark Muthiah; Cheng Han Ng
Journal:  Clin Mol Hepatol       Date:  2022-03-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.